would be nice to see a little more push from management, page-15

Companies compete for capital (particularly pre-revenue biotechs). Ensuring that you are well positioned requires both depth and breadth in communications. FTT currently has the depth as I'm sure everyone appreciates the detail provided in the trial updates. What FTT lacks however is breadth - a willingness to present the company to investors who have either never heard of the company or worse still associate it with the TIS days.

I think it was @Werble who drew the comparison to 1AD (apologies if it was another poster). 1AD have underdelivered on everything they promised at the IPO stage but the CEO's commitment to investor relations has ensured the share price is 50% higher than the IPO price despite all the setbacks. The most important consequence of this has meant that when the company has had to raise capital the dilution has been acceptable.

If I put FTT and 1AD side by side there is no doubt which company is delivering more scientific and business progress and yet the share market tells me the opposite.

Everyone of us is in sales in some capacity. Some of us just don't acknowledge it.